Previous close | 64.79 |
Open | 64.87 |
Bid | 65.01 x 1100 |
Ask | 65.02 x 1300 |
Day's range | 64.61 - 65.11 |
52-week range | 61.73 - 76.56 |
Volume | |
Avg. volume | 5,492,947 |
Market cap | 201.599B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 34.41 |
EPS (TTM) | 1.89 |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.24%) |
Ex-dividend date | 10 Aug 2023 |
1y target est | 82.69 |
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.